Hepatitis A Vaccines

Averhoff, Francisco; Khudyakov, Yury; Nelson, Noele P.

doi:10.1016/b978-0-323-35761-6.00024-9

Cited by 10 publications

(2 citation statements)

References 570 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sporadic outbreaks can occur in otherwise low endemicity countries [7]. Globally, >100 million HAV infections and 15,000-30,000 associated deaths occur annually [8]. The global burden of HAV in 2013 was estimated to be 1.2 million disability-adjusted life years (DALYs), 198,000 years lived with disability (YLDs), and 1.0 million years of life lost (YLLs) [9].…”

Section: Epidemiologymentioning

confidence: 99%

Clinical experience with the inactivated hepatitis A vaccine, Avaxim 80U Pediatric

Bravo

Mege

Vigne

et al. 2019

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Hepatitis A, caused by hepatitis A virus (HAV), is primarily transmitted via the fecal/oral route either through ingestion of contaminated food and water or through direct contact with an infectious person. Prevalence of hepatitis A is strongly correlated with socioeconomic factors, decreasing with increased socioeconomic development, access to clean water and sanitation. Vaccination against HAV should be part of a comprehensive plan for the prevention and control of viral hepatitis, either as part of regular childhood immunization programs or with other recommended vaccines for travelers. Areas covered: We present here evidence for the immunogenicity and safety of an inactivated HAV pediatric vaccine (Avaxim® 80U Pediatric, Sanofi Pasteur), indicated for use in children aged 12 months to 15 years. Data evaluated are from trials undertaken during the clinical development of this vaccine, a systematic literature review and post-market pharmacovigilance. Expert opinion: The pediatric HAV vaccine is highly immunogenic and generates long-lasting protection against hepatitis A disease in children. The safety and immunogenicity data presented in this review suggest that the pediatric HAV vaccine is a valuable option in the prevention of HAV infection in children in many areas of the world where the disease remains a healthcare issue.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Clinical experience with the inactivated hepatitis A vaccine, Avaxim 80U Pediatric

Bravo

Mege

Vigne

et al. 2019

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…WHO reports that in 2016, more than 7000 people died from hepatitis A worldwide [ 1 ]. To date, there is no specific treatment for HAV infection, although vaccines are available to prevent it [ 142 ].…”

Section: Hepatitis a Virusmentioning

confidence: 99%

CRISPR/Cas9 as a New Antiviral Strategy for Treating Hepatitis Viral Infections

Bartosh,

Dome,

Zhukova

et al. 2023

IJMS

View full text Add to dashboard Cite

Hepatitis is an inflammatory liver disease primarily caused by hepatitis A (HAV), B (HBV), C (HCV), D (HDV), and E (HEV) viruses. The chronic forms of hepatitis resulting from HBV and HCV infections can progress to cirrhosis or hepatocellular carcinoma (HCC), while acute hepatitis can lead to acute liver failure, sometimes resulting in fatality. Viral hepatitis was responsible for over 1 million reported deaths annually. The treatment of hepatitis caused by viral infections currently involves the use of interferon-α (IFN-α), nucleoside inhibitors, and reverse transcriptase inhibitors (for HBV). However, these methods do not always lead to a complete cure for viral infections, and chronic forms of the disease pose significant treatment challenges. These facts underscore the urgent need to explore novel drug developments for the treatment of viral hepatitis. The discovery of the CRISPR/Cas9 system and the subsequent development of various modifications of this system have represented a groundbreaking advance in the quest for innovative strategies in the treatment of viral infections. This technology enables the targeted disruption of specific regions of the genome of infectious agents or the direct manipulation of cellular factors involved in viral replication by introducing a double-strand DNA break, which is targeted by guide RNA (spacer). This review provides a comprehensive summary of our current knowledge regarding the application of the CRISPR/Cas system in the regulation of viral infections caused by HAV, HBV, and HCV. It also highlights new strategies for drug development aimed at addressing both acute and chronic forms of viral hepatitis.

show abstract

Hepatitis A Infections in Transplant

Lane

2020

Emerging Transplant Infections

View full text Add to dashboard Cite

Hepatitis A Vaccines

Cited by 10 publications

References 570 publications

Clinical experience with the inactivated hepatitis A vaccine, Avaxim 80U Pediatric

Clinical experience with the inactivated hepatitis A vaccine, Avaxim 80U Pediatric

CRISPR/Cas9 as a New Antiviral Strategy for Treating Hepatitis Viral Infections

Hepatitis A Infections in Transplant

Contact Info

Product

Resources

About